Movement Alert｜PHARMARON Rises 3.28% in Regular Trading, Interim Results Review Approaching Amid CXO Sector Strength

Market Focus

Aug 18

On August 18, PHARMARON rose 3.28% in regular trading, trading at 31.6 HKD/share, with turnover of 55.32 million HKD.

On the news front, the company's board of directors is scheduled to convene on August 20 to review and approve its first-half interim results. The company previously pre-announced H1 revenue of 7.472 billion to 7.665 billion yuan, representing year-over-year growth of 16%-19%. New signed orders grew over 30% year-over-year, with small molecule CDMO new orders surging more than 50%, indicating strong earnings visibility.

Meanwhile, the CXO sector continued its collective rally. Within the Life Sciences Tools and Services sector, GenScript Bio rose 6.9%, WuXi Bio gained 3.81%, and WuXi XDC advanced 3.62%, reflecting sustained industry recovery momentum driving sector-wide valuation repair.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/1190631875"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1190631875\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1190631875?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-18 10:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1190631875","market":"hk","top_or_hot":-1,"title":"Movement Alert｜PHARMARON Rises 3.28% in Regular Trading, Interim Results Review Approaching Amid CXO Sector Strength","media":"Market Focus","content":"<p><p>On August 18, PHARMARON rose 3.28% in regular trading, trading at 31.6 HKD/share, with turnover of 55.32 million HKD.</p><p>On the news front, the company's board of directors is scheduled to convene on August 20 to review and approve its first-half interim results. The company previously pre-announced H1 revenue of 7.472 billion to 7.665 billion yuan, representing year-over-year growth of 16%-19%. New signed orders grew over 30% year-over-year, with small molecule CDMO new orders surging more than 50%, indicating strong earnings visibility.</p><p>Meanwhile, the CXO sector continued its collective rally. Within the Life Sciences Tools and Services sector, GenScript Bio rose 6.9%, WuXi Bio gained 3.81%, and WuXi XDC advanced 3.62%, reflecting sustained industry recovery momentum driving sector-wide valuation repair.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜PHARMARON Rises 3.28% in Regular Trading, Interim Results Review Approaching Amid CXO Sector Strength</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜PHARMARON Rises 3.28% in Regular Trading, Interim Results Review Approaching Amid CXO Sector Strength\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-18 10:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 18, PHARMARON rose 3.28% in regular trading, trading at 31.6 HKD/share, with turnover of 55.32 million HKD.</p><p>On the news front, the company's board of directors is scheduled to convene on August 20 to review and approve its first-half interim results. The company previously pre-announced H1 revenue of 7.472 billion to 7.665 billion yuan, representing year-over-year growth of 16%-19%. New signed orders grew over 30% year-over-year, with small molecule CDMO new orders surging more than 50%, indicating strong earnings visibility.</p><p>Meanwhile, the CXO sector continued its collective rally. Within the Life Sciences Tools and Services sector, GenScript Bio rose 6.9%, WuXi Bio gained 3.81%, and WuXi XDC advanced 3.62%, reflecting sustained industry recovery momentum driving sector-wide valuation repair.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03759","symbol_name":"康龙化成","start_time":0,"source_url":"","article_id":"1190631875","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1190631875","pubTimestamp":1787018749,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 18, PHARMARON rose 3.28% in regular trading, trading at 31.6 HKD/share, with turnover of 55.32 million HKD.On the news front, the company's board of directors is scheduled to convene on...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03759":"康龙化成"},"translate_title":"走势提醒|康龙化成常规交易上涨 3.28%，CXO 板块走强，中期业绩审查临近","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03759":1},"content_text":"On August 18, PHARMARON rose 3.28% in regular trading, trading at 31.6 HKD/share, with turnover of 55.32 million HKD.On the news front, the company's board of directors is scheduled to convene on August 20 to review and approve its first-half interim results. The company previously pre-announced H1 revenue of 7.472 billion to 7.665 billion yuan, representing year-over-year growth of 16%-19%. New signed orders grew over 30% year-over-year, with small molecule CDMO new orders surging more than 50%, indicating strong earnings visibility.Meanwhile, the CXO sector continued its collective rally. Within the Life Sciences Tools and Services sector, GenScript Bio rose 6.9%, WuXi Bio gained 3.81%, and WuXi XDC advanced 3.62%, reflecting sustained industry recovery momentum driving sector-wide valuation repair.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}